Insider Trading Alert - HUM, SPLK, WNR, FNGN And PVTB Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 2, 2013, 167 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $696.00 to $31,440,000.00.

Highlighted Stocks Traded by Insiders:

Humana (HUM) - FREE Research Report

Christopher M Todoroff who is Sr. VP and General Counsel at Humana sold 6,000 shares at $105.50 on Dec. 2, 2013. Following this transaction, the Sr. VP and General Counsel owned 16,226 shares meaning that the stake was reduced by 27% with the 6,000-share transaction.

The shares most recently traded at $104.23, down $1.27, or 1.22% since the insider transaction. Historical insider transactions for Humana go as follows:

  • 4-Week # shares sold: 14,865
  • 12-Week # shares sold: 14,865
  • 24-Week # shares sold: 67,980

The average volume for Humana has been 1.2 million shares per day over the past 30 days. Humana has a market cap of $16.2 billion and is part of the health care sector and health services industry. Shares are up 51.52% year-to-date as of the close of trading on Monday.

Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in three segments: Retail, Employer Group, and Healthcare Services. The stock currently has a dividend yield of 1.04%. The company has a P/E ratio of 11.4. Currently there are 12 analysts that rate Humana a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HUM - FREE

TheStreet Quant Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Humana Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Boeing, Pure Storage, Activision Blizzard: 'Mad Money' Lightning Round

The Makings of Another Huge Rebound?

Healthcare Management Stocks Look Too Pricey for Activists

Tenet Dives After Worse Than Expected Quarter Leads to Lower 2017 Outlook